BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States

LAVAL, Quebec — In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, and including LifeSci Capital as lead manager and H.C. Wainwright & Co. and Bloom Burton as co-managers (collectively, the “Underwriters”), relating to the public offering of 25,000,000 common shares. The shares are being sold at a public offering price of US$8.00 per common share. Closing of the Offering is expected to occur on December 17, 2021, subject to the satisfaction of customary closing conditions. In addition, the Underwriters have been granted a 30-day option following the date hereof to purchase up to an additional 3,750,000 common shares from the Company. Read More